Viemed to Host Q1 2026 Earnings Call on May 6

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 21 2026

0mins

VMD-0.57%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Earnings Call Announcement: Viemed Healthcare will host its Q1 2026 earnings conference call on May 6, 2026, at 11:00 a.m. EDT, aimed at providing investors and analysts with updates on financial performance and business developments.
Participation Details: Interested parties can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International), ensuring global investors have convenient access to company information.
Live Audio Webcast: The call will be available via a live audio webcast, accessible through the provided link, which enhances transparency and broadens the reach of information dissemination, thereby strengthening investor relations.
Replay Availability: Following the live call, a replay will be accessible in the Investor Relations section of the company's website, ensuring that investors who cannot participate in real-time can still obtain relevant information, thus improving communication efficiency between the company and its investors.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy VMD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on VMD

About VMD

Viemed Healthcare, Inc. is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. The Company focuses on in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. The Company’s products and services include Home Medical Equipment, In-home sleep testing, and Healthcare staffing. Home Medical Equipment provides respiratory and other home medical equipment solutions, including home ventilation, bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP) devices, percussion vests, oxygen concentrators, breast pumps for women, respiratory devices and other medical equipment. It offers in-home sleep apnea testing services. The Company also provides healthcare staffing and recruitment services.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Healthcare Shift: Outpatient vs. Home Care Specialists

Jun 10 2026Fool

Surgical Solutions Network: Surgery Partners operates over 300 surgical centers across 30 states, generating more than $3.3 billion in revenue for FY 2025, a 6% increase despite a net loss of $77.9 million, highlighting its strategic focus on expanding market share.
Home Care Growth: Viemed Healthcare specializes in home-based respiratory care, achieving approximately $270.3 million in revenue for FY 2025, a 21% increase, with a net income of $14.9 million, indicating its success in addressing the needs of the aging population and chronic disease patients.
Financial Structure Comparison: Surgery Partners has a debt-to-equity ratio of 2.3x, indicating significant reliance on borrowed funds, while Viemed's ratio is only 0.1x, reflecting a conservative financial structure that aids flexibility during economic fluctuations.
Market Outlook Analysis: As insurance companies favor home care to reduce hospital costs, Viemed's revenue surged over 28% year-over-year in Q1 2026, with full-year growth projected at 17%, while Surgery Partners is expected to see only a 3% revenue increase.

Investment Comparison: Surgery Partners vs. Viemed Healthcare

Jun 10 2026NASDAQ.COM

Market Positioning: Surgery Partners operates over 300 surgical centers nationwide, generating over $3.3 billion in FY 2025 revenue, which grew by 6% despite a net loss of $77.9 million, indicating the short-term costs of its expansion strategy.
Financial Structure Comparison: Viemed Healthcare focuses on home-based respiratory care, achieving approximately $270.3 million in FY 2025 revenue, a 21% increase, with a net income of $14.9 million, showcasing its profitability and robust financial structure in a high-demand niche.
Regulatory Risk Assessment: Surgery Partners faces compliance risks from federal laws, with about $3.7 billion in debt potentially limiting its ability to respond to economic shifts, while Viemed Healthcare's reliance on Medicare reimbursement means policy changes can directly impact its revenue.
Future Growth Potential: Viemed Healthcare's revenue surged over 28% year-over-year in Q1 2026, with an expected annual growth of 17%, while Surgery Partners anticipates only a 3% revenue increase, highlighting Viemed's strong growth momentum in the home care market.

Viemed Healthcare Exceeds Q1 2026 Earnings Expectations

May 06 2026seekingalpha

Significant Revenue Growth: Viemed Healthcare reported Q1 revenue of $75.4 million, a 28% increase year-over-year, demonstrating the company's ongoing expansion in sleep and maternal health sectors, thereby enhancing its market competitiveness.
Improved Cash Flow: The company generated free cash flow of $2.6 million, a notable recovery from a negative $5.7 million in Q1 2025, indicating progress in capital efficiency and strengthening financial stability.
Guidance Upgrade: Viemed raised its 2026 net revenue guidance to a range of $312 million to $320 million, reflecting confidence in future performance, while also adjusting capital expenditure expectations to 9% to 10.5% of net revenue, highlighting a focus on capital utilization efficiency.
Patient Churn Risk: Despite strong momentum in new patient starts, the turnover rate is higher than expected due to NCD compliance issues, resulting in a net patient census of 12,089 at quarter-end, which poses short-term pressure on performance.

Viemed Healthcare Q1 Earnings Beat Expectations with Strong Revenue Growth

May 06 2026seekingalpha

Significant Revenue Growth: Viemed Healthcare reported Q1 revenue of $75.41 million, reflecting a 27.5% year-over-year increase, exceeding market expectations by $1.01 million, indicating strong demand and an increase in market share in the medical equipment sector.
Adjusted EBITDA Increase: The adjusted EBITDA for the quarter ended March 31, 2026, totaled $14.3 million, representing a 12% increase compared to the same period last year, showcasing ongoing improvements in operational efficiency and cost control, which enhance profitability.
Strong Cash Flow Performance: The net cash provided by operating activities for the quarter was $8.1 million, with a total of $57.1 million over the trailing twelve months, demonstrating robust cash management that supports future investments and expansion.
Updated 2026 Guidance: The company has revised its 2026 revenue guidance to a range of $312 million to $320 million, up from the previous range, reflecting positive trends in new patient starts and an optimized revenue mix, which further boosts market confidence.

Viemed Healthcare to Announce Q1 Earnings on May 6

May 05 2026seekingalpha

Earnings Announcement: Viemed Healthcare is set to release its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $0.09, reflecting a significant 50% year-over-year increase, indicating strong profitability improvements.
Revenue Expectations: Analysts forecast that VMD's Q1 revenue will reach $74.4 million, representing a 25.9% year-over-year growth, which will further solidify the company's market position in the healthcare sector.
Performance Beat Record: Over the past year, Viemed Healthcare has beaten EPS and revenue estimates 75% of the time, demonstrating the company's financial stability and effective management execution.
Share Repurchase Program: Viemed Healthcare has authorized a share repurchase program through March 2027, which not only reflects the company's confidence in its stock value but also has the potential to provide additional returns to shareholders.